• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20001 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria]
2011     Andalusian Health Technology Assessment Area (AETSA) [Eculizumab (Soliris®) Assessment of effectivity and safety of the drug and economic analysis of use in Paroxysmal Nocturnal Haemoglobinuria therapy]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of transanal endoscopic microsurgery]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Economic evaluation of the molecular diagnosis of the influenza virus]
2012     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Economic evaluation of the introduction of the HPV vaccine in Spain to prevent cervical cancer]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Economic evaluation of the first TNF-alpha inhibitor therapy in patients with rheumatoid arthritis]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Economic evaluation of single tooth replacement: dental implant vs. bridge]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of preimplantation genetic diagnosis (PGD) for screening]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of photoselective vaporization treatment for benign prostatic hyperplasia]
2010     Andalusian Health Technology Assessment Area (AETSA) [Economic evaluation of monitoring systems of ketones in blood for the diagnosis and prevention of ketoacidosis]
2011     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of laparoscopic versus conventional surgery in gastrointestinal surgery]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Economic evaluation of joint replacement surgery alongside a multi-centre randomized trial in elderly patients with displaced femoral neck fractures]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of drug eluting stents in the treatment of ischemic heart disease (update)]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of drug eluting stents for high risk indications]
2015     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Economic evaluation of different strategies for screening for Chagas' disease in Spain]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Economic evaluation of carotid artery stenting compared with carotid endarterectomy in patients with carotid artery stenosis]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Economic evaluation of a telemonitoring intervention from primary care in home care patients with cardiac insufficiency and/or chronic bronchial disorders: Cost-effectiveness analysis, TELBIL study]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Economic evaluation of a pneumococcal vaccination program in a pediatric population]
2008     Andalusian Health Technology Assessment Area (AETSA) [Economic assessment of mitral valve insufficiency treatment]
2008     Andalusian Health Technology Assessment Area (AETSA) [Economic assessment of mitral valve insufficiency treatment]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic assessment of genetic test in breast cancer treatment]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Economic assessment guide in the health sector]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Economic analysis of peripherally inserted central venous catheters (PICC), inserted by nursing staff, in cancer and hematological patients]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Early diagnostic and treatment of caries in the primary teeth- a health technology assessment]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of mucopolysaccharidosis and oligosaccharidosis by population screening in the newborn period. Systematic review]
1994     Basque Office for Health Technology Assessment (OSTEBA) [Early detection of breast cancer in the Basque Country]
2010     The Swedish Council on Health Technology Assessment (SBU) [Early and focused ultrasonography in physical trauma]
2015     Basque Office for Health Technology Assessment (OSTEBA) [E-health systems to support cancer patients: proposal for the design of future assessment studies]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [E-health in caring for patients with atopic dermatitis. An economic evaluation comparing usual care with Internet-guided monitoring and self-management training by a nurse practitioner]
2014     The Swedish Council on Health Technology Assessment (SBU) [Dyslexia in children and adolescents – tests and interventions]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic stabilization with interspinous devices for spinal conditions]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging in pelvic floor dysfunction]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging for focal liver lesion assessment]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging for focal liver lesion assessment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic fixation for spine degenerative diseases]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Duodeno-jejunal bypass liner (DJBL) for patients with obesity, with/without type 2 diabetes mellitus]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (Addendum to Commission A15-07)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dual target deep brain stimulation in refractory dystonia]
2008     Norwegian Knowledge Centre for the Health Services (NOKC) [Dual diagnoses – severe mental illness and substance use disorder. Part 2 – Effect of psychosocial interventions]
2007     Norwegian Knowledge Centre for the Health Services (NOKC) [Dual diagnoses - substance use disorder and severe mental illness. Part 1 - accuracy of screening- and diagnostic instruments]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Drugs in oncology: an overview of benefit and refund practices in Europe]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Drugs for smoking cessation]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Drug-eluting stents with rapamycin or paclitaxel versus conventional stents]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease]
2009     National Evidence-based Healthcare Collaborating Agency (NECA) [Drug-eluting stents versus bare-metal stents in acute myocardial infarction]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting stents in coronary heart disease]
2014     The Swedish Council on Health Technology Assessment (SBU) [Drug-eluting stents in coronary arteries]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting balloon for the treatment of coronary stenosis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilatation catheter for transurethral treatment of urethral strictures - Addendum to commission H20-02]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon catheter for the transurethral treatment of urethral strictures - Second addendum to commission H20-02]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Drug treatment of children with respiratory tract infections - a scoping review]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug treatment of ADHD (Attention Deficit/Hyperactivity Disorder) in adults in Germany]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Drotrecogin alfa in the treatment of severe sepsis]
2011     Haute Autorite de sante (HAS) [Dressings: indications and recommended uses]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2009     The Swedish Council on Health Technology Assessment (SBU) [Dopaminergic agents in treating restless legs syndrome]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Domiciliary oxygen therapy]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dolutegravir, Abacavir and Lamivudine (Triumeq®) in HIV infection]
2020     National Committee for Technology Incorporation (CONITEC) [Dolutegravir for the treatment of pregnant women living with HIV]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection) - Addendum to commission A17-11]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2002     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [DMARD therapy of rheumatoid arthritis, systematic review of the clinical and economic literature]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Dissemination of HTA products. New lines of action]
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Disinfection chambers/tunnels in the context of COVID-19 pandemic]
2013     Norwegian Knowledge Centre for the Health Services (NOKC) [Discharging patients with chronic disease: effect of various forms of cooperation between hospital and the community health service]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Diroximel fumarate (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Direct-acting oral anticoagulants for postoperative thrombosis prophylaxis]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 inhibitors as treatment for diabetes mellitus]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl peptidase-4 (dpp4) inhibitors in diabetes mellitus]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Diode laser vaporization in benign prostatic hyperplasia]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dinutuximab for patients with high-risk neuroblastoma]